Europeiska unionen - svenska - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - läkemedel som används vid diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillägg till andra läkemedel för behandling av typ 2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 och 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Europeiska unionen - svenska - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - läkemedel som används vid diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillägg till andra läkemedel för behandling av typ 2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 och 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Europeiska unionen - svenska - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - läkemedel som används vid diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 och 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - dapagliflozin - filmdragerad tablett - 10 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; dapagliflozin 10 mg aktiv substans; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - dapagliflozin - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; mannitol hjälpämne; dapagliflozin 5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - dapagliflozinpropandiolmonohydrat - filmdragerad tablett - 10 mg - dapagliflozinpropandiolmonohydrat 12,3 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - dapagliflozinpropandiolmonohydrat - filmdragerad tablett - 5 mg - dapagliflozinpropandiolmonohydrat 6,15 mg aktiv substans; laktosmonohydrat hjälpämne